Roche Holding AG (RHHBY)
| Previous close | 33.95 |
| Open | 34.47 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 33.93 - 34.47 |
| 52-week range | 33.70 - 43.32 |
| Volume | |
| Avg. volume | 1,558,660 |
| Market cap | 220.83B |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | 18.24 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.28 (3.77%) |
| Ex-dividend date | 16 Mar 2023 |
| 1y target est | N/A |
- GlobeNewswire
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Lati
- Business Wire
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
SOUTH SAN FRANCISCO, Calif., October 02, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new data for Ocrevus® (ocrelizumab) and investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib for multiple sclerosis (MS), and Enspryng® (satralizumab) for neuromyelitis optica spectrum disorder (NMOSD). In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Resear
- GlobeNewswire
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conference Basel, 7 September 2023 - Roche
